{
    "clinical_study": {
        "@rank": "16514", 
        "arm_group": [
            {
                "arm_group_label": "1. Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }, 
            {
                "arm_group_label": "2.0", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and\n      immunogenicity of single escalating doses PF-06342674."
        }, 
        "brief_title": "A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male subjects and female of non-childbearing potential subjects between the ages of\n             18 and 55.\n\n          -  BMI between 18.5 to 32 kg/m2.\n\n          -  Total body weight \u226540 kg and \u2264120 kg.\n\n        Exclusion Criteria:\n\n          -  Previous treatment with an antibody within 6 months prior to Day 1.\n\n          -  Pregnant or nursing females; females of childbearing potential.\n\n          -  History of sensitivity to heparin or heparin-induced thrombocytopenia."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "76", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01740609", 
            "org_study_id": "B4351001"
        }, 
        "intervention": [
            {
                "arm_group_label": "1. Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2.0", 
                "description": "Single SC Dose", 
                "intervention_name": "PF-06342674 Dose A", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "2.0", 
                "description": "Single SC Dose", 
                "intervention_name": "PF-06342674 Dose B", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "2.0", 
                "description": "Single SC Dose", 
                "intervention_name": "PF-06342674 Dose C", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "2.0", 
                "description": "Single SC Dose", 
                "intervention_name": "PF-06342674 Dose D", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "2.0", 
                "description": "Single SC Dose", 
                "intervention_name": "PF-06342674 Dose E", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "2.0", 
                "description": "Single IV Dose", 
                "intervention_name": "PF-06342674 Dose F", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "2.0", 
                "description": "Single SC Dose", 
                "intervention_name": "PF-06342674 Dose G", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "2.0", 
                "description": "Single IV Dose", 
                "intervention_name": "PF-06342674 Dose H", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "2.0", 
                "description": "Single SC Dose", 
                "intervention_name": "PF-06342674 Dose I", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "2.0", 
                "description": "Single IV Dose", 
                "intervention_name": "PF-06342674 Dose J", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1", 
            "RN168", 
            "Healthy Volunteers"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4351001&StudyName=A%20Study%20To%20Assess%20The%20Safety%20Of%20PF-06342674%20In%20Healthy%20Volunteers"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of Pf-06342674 (RN168) In Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of dose limiting or intolerable treatment related AEs", 
                "safety_issue": "Yes", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Incidence of treatment emergent AEs", 
                "safety_issue": "Yes", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Incidence of abnormal laboratory findings", 
                "safety_issue": "Yes", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Changes from baseline in safety laboratory assessments", 
                "safety_issue": "Yes", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Abnormal and clinically relevant changes in vital signs, blood pressure, and ECG parameters", 
                "safety_issue": "Yes", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Incidence of anti-drug-antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Severity of treatment emergent AEs", 
                "safety_issue": "Yes", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Causal relationship of treatment emergent AEs", 
                "safety_issue": "Yes", 
                "time_frame": "60 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01740609"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.", 
                "measure": "Area under the Concentration-Time Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "measure": "PK parameter estimates including T1/2.", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "description": "CL is a quantitative measure of the rate at which a drug substance is removed from the body.", 
                "measure": "Systemic Clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}